The METEOR study was the registration trial for cabozantinib in RCC and led to the US Food and Drug Administration (FDA) approval in advanced RCC previously treated with a VEGF receptor (VEGFR)
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The therapies and the sequence thereof will most likely change in RCC.
The first-line therapy will likely be an immune therapy combination such as ipilimumab and nivolumab or bevacizumab and atezolizumab, as both these combinations have completed phase III trials in comparison with sunitinib. There will be a domino effect in the second-line setting, depending on which first-line therapy is chosen. Multiple novel agents continue to be tested in clinical trials and hopefully biomarker-driven therapeutic choice will be validated in the future.
